HEALTHCARE PROFESSIONAL RESOURCE CENTER — This site is intended for U.S. Healthcare Professionals only

Registration

Complete the following three sections below to create your all-access account
 

1. Profile information

All fields are required unless specified

2. Professional Information

3. Consent and releases

I declare that I am a licensed Healthcare Professional and I want to register for the PANCREAZE Advantage Healthcare Professional Resource Center. This declaration authorizes VIVUS to contact me and confirm and validate the professional information provided during the registration process.

 

I understand that by clicking the “SUBMIT” button below, and registering for the PANCREAZE Advantage Healthcare Professional Resource Center, and by using this website, I am authorizing VIVUS or its designee to contact me by telephone, direct mail or email. For more information about VIVUS’ privacy practices please view the Privacy Policy.

Indication

PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PANCREAZE (pancrelipase) exceed 2,500 lipase units/kg body weight per meal (or greater than 10,000 lipase units/kg body weight per day).

Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.

To avoid irritation of oral mucosa, do not chew PANCREAZE or retain in the mouth.

There is theoretical risk of viral transmission with all pancreatic enzyme products including PANCREAZE.

Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.

Most common adverse reactions (≥ 10%) are: abdominal pain, flatulence, diarrhea, abnormal feces, and fatigue.

PANCREAZE is not interchangeable with any other pancrelipase products.

Dosing should not exceed the recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines.

 
Please click here for the PANCREAZE Medication Guide and Full Prescribing Information.

 
References: 1. PANCREAZE Full Prescribing Information. Campbell, CA: VIVUS, Inc; 2018.
2. Trapnell BC, et al. Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros. 2011;10(5):350-35 6.

Important Safety Information

Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PANCREAZE (pancrelipase) exceed 2,500 lipase units/kg body weight per meal (or greater than 10,000 lipase units/kg body weight per day).

Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.

VIEW ALL +